While certain nucleos(t)ide reverse transcriptase inhibitors (NRTIs) are efficacious in treating HBV infection, their effects are yet to be optimized and the emergence of NRTI-resistant HBV variants is an issue because of the requirement for lifelong treatment. The development of agents that more profoundly suppress wild-type and drug-resistant HBVs, and that have a long-acting effect, are crucial to improve patient outcomes.

Authors: Nobuyo Higashi-Kuwata, Sanae Hayashi, Hiroki Kumamoto, Hiromi Ogata-Aoki, Debananda Das, David Venzon, Shin-Ichiro Hattori, Haydar Bulut, Mai Hashimoto, Masaki Otagiri, Nobutoki Takamune, Naoki Kishimoto, David A Davis, Shogo Misumi, Masakazu Kakuni, Yasuhito Tanaka, Hiroaki Mitsuya

Read publication

Back to Resources